EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 9th, 2018 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Executive Employment Agreement (the “Agreement”) is entered into between Audentes Therapeutics, Inc. (the “Company”) and (the “Executive”). This Agreement is effective as of , 20 (the “Effective Date”). [This Agreement supersedes and replaces in its entirety the dated , between Executive and the Company.]1
FIRST AMENDMENT TO License AgreementLicense Agreement • March 9th, 2018 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO LICENSE AGREEMENT (“First Amendment”) is entered into as of November 3, 2017 (“First Amendment Effective Date”) by and between REGENXBIO Inc., a corporation organized under the laws of the State of Delaware, with offices at 9600 Blackwell Road, Suite 210, Rockville, MD 20850 (“Licensor”), and Audentes Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at 600 California Street, 17th Floor, San Francisco, California, 94108 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and collectively as the “Parties.”
FOURTH AMENDMENT TO EXCLUSIVE LICENSE AND COLLABORATION AGREEMENTExclusive License and Collaboration Agreement • March 9th, 2018 • Audentes Therapeutics, Inc. • Biological products, (no disgnostic substances)
This FOURTH AMENDMENT (“Fourth Amendment”) is entered into as of December 20th, 2017 (the “Fourth Amendment Effective Date”) by and between Audentes Therapeutics Inc., having its principal offices at 600 California Street, 17th Floor, San Francisco, CA 94108 (“Audentes”), and The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation, with offices located at Penn Center for Innovation, 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104-6228 (“Penn”). Audentes and Penn are referred to collectively as the “Parties” and individually as a “Party.”
